New Recommendations Spotlight Exercise-Based Interventions to Boost Function in Patients With Lung Cancer
CAMPASS: Benmelstobart Plus Anlotinib Shows Superior PFS in PD-L1 Positive Advanced NSCLC
ALK Positive at ASCO 2025: Ken Culver, MD, Reflects on Experiences, Importance of Patient Advocacy
SACHI: Savolitinib Plus Osimertinib Prolongs PFS Versus Chemotherapy in MET-Driven EGFR-Mutated NSCLC
Long-Term Survival in Unresectable Malignant Peritoneal Mesothelioma With PIPAC: A Case Report
SOHO-02 Trial Investigates BAY 2927088 as Frontline Treatment for HER2-Positive NSCLC